- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Novotech Selects ObvioGo for Multi-Trial Digital Delivery
Partnership establishes standardized digital foundation to scale clinical trials globally
Published on Feb. 24, 2026
Got story updates? Submit your updates here. ›
ObvioHealth, a leader in digital clinical trial solutions, has announced a strategic multi-trial licensing agreement with Novotech, a globally recognized full-service clinical research organization (CRO). Under the agreement, Novotech will license ObvioGo®, an enterprise platform for participant-facing trial workflows, across multiple clinical trials to support decentralized and hybrid study designs at scale.
Why it matters
As decentralized and hybrid clinical trials continue to evolve, sponsors need scalable digital solutions that can deliver consistent, patient-centric experiences across global programs. This partnership reinforces ObvioHealth’s role as a trusted enterprise technology partner and supports Novotech’s investment in more efficient, digitally-enabled development models.
The details
The multi-trial license allows Novotech teams to reuse standardized digital workflows across programs, accelerating study start-up while maintaining consistency across regions and therapeutic areas. ObvioGo combines eConsent, ePRO/eCOA, and remote/hybrid assessments in a single system, enhancing participant engagement and streamlining trial participation.
- The agreement was announced on February 24, 2026.
The players
ObvioHealth
A global leader in digital clinical trial solutions, delivering enterprise-grade technology to support decentralized, hybrid, and site-based studies.
Novotech
A globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies.
Ivan Jarry
CEO of ObvioHealth.
Michael Stibilj
COO at Novotech.
What they’re saying
“Standardization is becoming foundational to how clinical trials are delivered at scale. This partnership with Novotech builds on our existing relationship and reflects that shift, reinforcing our focus on consistent, scalable digital execution across global programs.”
— Ivan Jarry, CEO of ObvioHealth (PRNewswire)
“As decentralized and hybrid trials continue to evolve, sponsors need solutions that are both flexible and scalable. By licensing ObvioGo across multiple studies, we're able to deliver adaptable, patient-centric tools that enhance engagement, streamline trial participation, and support more efficient, consistent execution for sponsors and sites.”
— Michael Stibilj, COO at Novotech (PRNewswire)
What’s next
The multi-trial licensing agreement will enable Novotech to leverage ObvioGo across its global clinical trial portfolio, supporting the delivery of decentralized and hybrid studies at scale.
The takeaway
This partnership demonstrates the growing importance of standardized, enterprise-grade digital solutions in the clinical trial industry. By licensing ObvioGo, Novotech can provide sponsors with a consistent, scalable platform to enhance participant engagement and streamline trial execution across multiple global programs.
